Connect with us

Stock Market

Moderna COVID-19 Vaccine 95% Effective in Trial, Shares Gained 10.69%

Published

4 years ago

on

Moderna on Monday announced its COVID-19 vaccine is 94.5 percent effective in a trial of 30,000 patients.

This was much higher than the over 90 percent efficiency announced by Pfizer and BioNTech of Germany about a week ago.

Moderna could get emergency user authorisation from FDA by the end of the year given the available information.

The company’s share rose by 9.67 percent or $8.64 to $98.03 per share on Monday following the official announcement.

While Pfizer shares declined by 3.63 percent or $1.40 to $37.22 per share as investors are now leaning towards Moderna.

Moderna, an American biotechnology company based in Cambridge, Massachusetts, focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA.

Is the CEO and Founder of Investors King Limited. He is a seasoned foreign exchange research analyst and a published author on Yahoo Finance, Business Insider, Nasdaq, Entrepreneur.com, Investorplace, and other prominent platforms. With over two decades of experience in global financial markets, Olukoya is well-recognized in the industry.

Comments
Advertisement
Advertisement